The anti-obesity effects ofLactobacillus caseistrain Shirota versus Orlistat on high fat diet-induced obese rats
Golgis KarimiMohd Redzwan SabranRosita JamaluddinKolsoom ParvanehNorhafizah MohtarrudinZuraini AhmadHuzwah Khaza’aiAlireza Khodavandi
96
Citation
54
Reference
10
Related Paper
Citation Trend
Abstract:
Obesity and overweight are major public health problems. Various factors, such as daily nutritional habits, physical inactivity, and genetic, are related to the prevalence of obesity. Recently, it was revealed that the gut microflora may also play an important role in weight management. Thus, this study aimed to determine the anti-obesity effects of Lactobacillus casei strain Shirota (LcS) compared with those of orlistat in an animal model fed a high-fat diet (HFD).Thirty-two male Sprague-Dawley rats were assigned to four groups fed various diets as follows: a standard diet group, HFD group, HFD supplemented with LcS (108109 colony-forming units (HFD-LcS) group, and HFD group treated with Orlistat (10 mg/kg body weight)). After 15 weeks, the weights of organs, body weight, body fat mass and serological biomarkers were measured. In addition, histological analysis of the liver and adipose tissue was performed.Body weight, body mass index, fat mass, leptin and glucose levels were lower, and high-density lipoprotein and adiponectin levels were higher in the HFD-LcS and HFD-orlistat groups than in the HFD group. In addition a significant difference in body fat mass was observed between HFD-LcS group with HFD-orlistat group (19.19±5.76 g vs. 30.19±7.98 g). Although the interleukin-6 level was significantly decreased in the HFD-LcS and HFD-orlistat groups compared with the HFD group, no significant change was observed in other inflammatory biomarkers.The results of the present study show that LcS supplementation improves body weight management and the levels of some related biomarkers. In addition, LcS supplementation showed a better result in fat mass and alanine aminotransferase reduction than Orlistat. Further studies are needed to elucidate the anti-obesity effects of LcS, with a longer period of supplementation.Keywords:
Orlistat
Lactobacillus casei
Anti obesity
The present work was designed to evaluate the effectiveness of the orlistat drug on some hormones and biochemical parameters in male rats received a high fat diet (HFD).Twenty-four rats were divided into four groups: 1st group administered normal diet, 2 nd group administered HFD, the 3rd group administered HFD plus 9.5 mg/kg b.w./day orlistat, and the 4th group administered HFD diet plus 19 mg/kg b.w./day orlistat.The experimental period was for four weeks.At the end of the experiment, blood samples were obtained for biochemical and hormonal assays.The administration of HFD for four weeks increased significantly the weight gain, serum total cholesterol (TC), triglycerides (TAG), low density lipoprotein (LDL-c), glucose, insulin, triiodothyronine (T3), thyroxine (T4), leptin, with the significant decrease in high density lipoprotein (HDL-c), ghrelin, thyrotropin (TSH) and testosterone hormones in the serum as compared with the control group.The treatment with orlistat neutralized the levels of the measured parameters as compared with HFD fed rats and the results were correlated with the dose of orlistat.In conclusion, an improvement was observed in the biochemical and hormonal results by the treatment with orlistat drug.
Orlistat
Anti obesity
Cite
Citations (1)
Orlistat first became available (as 120 mg capsules [Xenical]) around 10 years ago as a prescription-only treatment for obesity. Earlier this year, orlistat 60 mg capsules (alli - GlaxoSmithKline Consumer Healthcare) became available for sale without a prescription to the public in the European Union. Orlistat 60 mg is available in the UK as a Pharmacy (P) medicine and so can be purchased over-the-counter (OTC) from pharmacies. OTC orlistat is promoted as a new weight loss aid, "boosting weight loss by 50%" when added to a reduced calorie, lower-fat diet. Here we review the place of OTC orlistat in tackling obesity.
Orlistat
Anti obesity
Over-the-counter
Cite
Citations (4)
Obesity is the serious problem now a day. From the ancient days investigation is going on many drugs which are employing to treat not only obesity but also the disorders arises due to the obesity. Many drugs and treatments are available in the market to treat obesity now. But no drug is ideal to treat all sort problems of obesity. Still the research is going on for the ideal drug. As a part of research work on drug development process for obesity the preclinical research is mandatory to evaluate the drug activity. Normally rodents are the organisms for first stage of drug evaluation and the obesity could be induce by using chemicals and high fat diet. These two methods are ideal methods for induction of obesity in rodents. In the present study of evaluation of anti obesity activity the organisms used were albino mice. The standard drug used was orlistat. The two test doses of methanolic extract of pericarps of flowers of Sapindus emarginatus were prepared. The total evaluation period was 28 days.
Orlistat
Anti obesity
Cite
Citations (1)
Orlistat
Anti obesity
Cite
Citations (2)
The global prevalence of obesity is on the increase, hence the development of a
safer and more effective anti-obesity therapeutic approach is becoming more of an imperative.
Objective: The study is to investigate whether Orlistat and Garlic can alter antioxidant property
and lipid profile of high fat diet induced- obese Sprague-Dawley rats. Methods: Sixty–four
albino Sprague-Dawley rats (170.62 ± 5.74g), were divided into two equal groups. Group A rats
were fed with commercial chow diet, while group B rats were fed with chow and fat emulsion
to induce obesity in rats for 30days. The rats in group B were divided into 4 groups of 8 rats
each) and treated with Orlistat drug (5mg/kg body weight), Garlic extract (5ml) and a
combination of both for 5 weeks. Results: Treatment with Orlistat and Garlic extracts and a
combination of both significantly (p<0.01) reduced the lipid profile of the high fat induced
obese rat. However, administration with Orlistat and Garlic in rats significantly (p<0.05)
ameliorated hepatic and renal functions as observed in high-fat diet treated groups. Serum ALT,
AST activities, LDL, triglycerides and total cholesterol levels were significantly (P<0.05) higher
in the high fat group compared with control. Conclusion: Data of the study indicate that oral
administration of Orlistat and / or Garlic extracts curtailed anti-oxidant enzymes activities
and ameliorated high-fat diet induced obese Sprague-Dawley rats.
Orlistat
Anti obesity
Lipid Profile
Cite
Citations (4)
Orlistat
Anti obesity
Cite
Citations (0)
Orlistat
Rimonabant
Anti obesity
Cite
Citations (4)
Orlistat
Anti obesity
Diet-induced obese
Cite
Citations (0)
이 연구의 목적은 30-40대 남성 근로자에 있어서 대사증후군 구성인자와 adiponectin 및 leptin의 생리적 농도가 비만에 미치는 영향을 보고자 하였다. 방법: 체질량지수(BMI) 측정은 체성분분석기, 혈압과 혈청생화학 검사는 수은혈압계와 자동생화학분석기를 이용하여 측정하였다. Adiponectin과 leptin은 ELISA kit으로 분석하였고, 대사증후군은 NCEP-ATP III 진단기준에 의하여 진단하였다. 결과: 허리와 엉덩이둘레, 체지방, 수축기와 이완기 혈압은 BMI≤25 ㎏/㎡보다 BMI>25 ㎏/㎡군에서 유의하게 높았다. BMI>25 ㎏/㎡군에서 공복혈당, 인슐린, 인슐린저항성과 leptin의 농도가 BMI≤25 ㎏/㎡군보다 높은 반면, HDL-콜레스테롤과 adiponectin의 농도는 BMI≤25 ㎏/㎡군에서 높았다. 연령, 흡연 및 음주습관을 보정한 후, 다중 로지스틱 회귀분석 실시결과 규칙적인 운동, adiponectin과 leptin은 비만하지 않은(BMI≤25 ㎏/㎡) 남성 근로자에서 대사증후군 유발에 관여하는 독립적 인자로 나타났다. 결론: 이 연구결과 남성의 비만은 대사증후군의 되먹임 조절에 관여하는 adiponectin과 leptin의 생리적 농도와 관련이 있으며, adiponectin과 leptin과 같은 신경영양물질의 변화와 관련되어 되먹임 조절의 기능손상과 저하는 궁극적으로 대사증후군을 유발시킬 수 있다.
Cite
Citations (0)